Investor Presentaiton
Financial Results for FY2022
Revenue of Major Products in Japan
Billions of yen
Change
FY2021
FY2022
Results
Results
Value
%
EquaⓇ/EquMetⓇ
37.5
33.6
(4.0)
(10.5)
TrulicityⓇ*
33.6
24.8
(8.8)
(26.2)
TRERIEFⓇ
16.4
16.7
0.3
1.8
Sales collaboration of TrulicityⓇ
terminated at the end of
December 2022
LATUDAⓇ
6.9
9.6
2.7
39.3
LATUDAⓇ showing steady growth
METGLUCO®
8.1
7.7
(0.4)
(5.5)
LONASEN® Tape
2.1
2.9
0.9
42.8
TWYMEEGⓇ
0.2
2.2
2.0
AG products
9.7
9.2
(0.5)
(5.2)
Prescription days limit of
TWYMEEGⓇ was lifted in
September 2022
Others
35.5
19.5
(16.0)
(45.1)
Total
149.9
126.1
(23.8) (15.9)
Sale of REPLAGALⓇ included in
"Others" decreased (FY2021:
¥12.4B)
Note: Sales of each product are shown by invoice price (* TrulicityⓇ is shown by NHI price)
Sumitomo Pharma
NHI price revision affected
(¥10.9B) the Japan segment total
© Sumitomo Pharma Co., Ltd. All Rights Reserved.
4View entire presentation